Skip to content

8-KAccepted Aug 6, 8:15 AM ET

Corbus Pharmaceuticals Reports Quarterly Results Ended June 30, 2026

CRBPCorbus Pharmaceuticals Holdings, Inc.

Accepted (ET)

8:15 AM

Aug 6, 2026

Filed

Aug 6, 2026

Documents

10

Size

432.2 KB

Summary

Corbus Pharmaceuticals Reports Quarterly Results Ended June 30, 2026

Updated

What Happened
Corbus Pharmaceuticals Holdings, Inc. announced on August 6, 2026 that it issued a press release disclosing financial information and operating metrics for the fiscal quarter ended June 30, 2026 and discussed its business outlook. The company filed the information on Form 8-K (Item 2.02) and attached the press release as Exhibit 99.1.

Key Details

  • Press release date and 8-K filing: August 6, 2026.
  • Reporting period: fiscal quarter ended June 30, 2026.
  • The press release with the results and outlook is furnished as Exhibit 99.1 to the Form 8-K.
  • The Form 8-K was signed on behalf of the company by CEO Yuval Cohen.

Why It Matters
This 8-K delivers the company’s latest quarterly results and operating metrics and provides management’s short-term business outlook—information investors use to assess recent performance, cash runway, and near-term prospects. Retail investors should read the attached press release (Exhibit 99.1) for specific numbers on revenue, expenses, cash position, and any guidance or forward-looking commentary the company provided.

AI-written summary · check the filing